Benzinga · Oct 16, 2026
UCB Scores FDA Win With First-Of-Its-Kind Daily Autoinjector for Rare Muscle Disorder
FDA approves UCB's ZILBRYSQ autoinjector for generalized myasthenia gravis, offering a new once-daily self-administration option.
UC
OTC · UCBJY
UCB S.A.
Healthcare · Biotechnology
$122.32
Up+$8.11 (+7.10%)
Updated Oct 21, 2026, 4:35 AM
SID Score
5.8/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 53.81B
- P/E ratio
- 34.37
- Dividend yield
- 0.65%
- 52-week range
- — – —
- Volume
- 4.32K
- Avg. volume
- 29.22K
Price performance · UCBJY
UCBJY price history
1M range · 0 trading sessions · Daily adjusted prices
UCBJY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest UCBJY news
The latest Smart Investors Daily articles mentioning UCBJY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
UCBJY research
Overview
Company profile and research snapshot.
Company profile
UCB SA UNSP/ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- —
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 22, 2026 | TD COWEN | Buy | — |
| Sep 21, 2026 | BERENBERG | Buy | — |
| Sep 17, 2026 | BAADER EUROPE / ALPHAVALUE | Buy | — |
| Sep 4, 2026 | JEFFERIES | Hold | — |
| Sep 1, 2026 | DEGROOF PETERCAM | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 10, 2026
Is UCB (ENXTBR:UCB) Undervalued As It Expands Its Biologics Campus In Georgia?
UCB (ENXTBR:UCB) just dedicated the future site of a large biologics manufacturing campus in Gwinnett County, Georgia, marking a roughly €2b U.S. expansion that investors may view as a long-horizon capacity build. For context, UCB’s €203.5 share price comes after a 90 day share price return that declined 14.17% and a one year total shareholder return that declined 20.16%. This is in contrast to the three and five year total shareholder returns of 158.52% and 115.49%, which point to stronger...
SeekingAlpha · Oct 8, 2026
UCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology Transcript
UCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology October 1, 2026 8:30 AM EDTCompany ParticipantsYvonne Naughton...
SeekingAlpha · Sep 23, 2026
UCB SA (UCBJY) Presents at J.P. Morgan CEO Call Series Transcript
UCB SA (UCBJY) J.P. Morgan CEO Call Series September 23, 2026 11:15 AM EDTCompany ParticipantsJean-Christophe Tellier - CEO & Executive...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
